Novartis Investigative Site

Szeged H-6725

4 studies enrolling now · 83 studies all time

What they study most

Acute Leukaemia, Acute Myeloid Leukemia, Acute Myocardial Infarction, Advanced Metastatic Breast Cancer, Anti-Dyskinesia Agents, Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis, Asthma, Atherosclerosis, Atherosclerotic Cardiovascular Disease, Atopic Dermatitis, Basal Cell Carcinoma, Breast Cancer

Studies at this site

• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V — Recruiting now
• TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) — Recruiting now
• Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET — Recruiting now
• Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events — Running, not enrolling
• A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. — Running, not enrolling
• Iptacopan in Patients With ANCA Associated Vasculitis — Running, not enrolling
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) — Completed
• Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome — Running, not enrolling
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
• Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome — Completed
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) — Completed
• Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma — Completed
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients — Completed
• Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome — Completed
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma — Stopped early
• Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients — Completed
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib — Completed
• A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines — Completed
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer — Completed
• Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS) — Completed
• Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) — Completed
• Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma — Stopped early
• Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines — Stopped early
• Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne — Completed
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion — Stopped early
• A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer — Completed
• Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD — Completed
• Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema — Completed
• Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• Systemic Corticosteroids Avoidance Study in Severe Asthma Patients — Stopped early
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis — Completed
• A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension — Completed
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma — Completed